MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE: RESULTS FROM THE PILOT MOSAICC STUDY

Lesley Anderson; Glen James; Andrew S Duncombe; Ruben Mesa; Robyn Scherber; Amylou Dueck; Frank De Vocht; Michael Clarke; Mary McMullin

MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE: RESULTS FROM THE PILOT MOSAICC STUDY

Lesley Anderson, Glen James, Andrew S Duncombe, Ruben Mesa, Robyn Scherber, Amylou Dueck, Frank De Vocht, Michael Clarke, Mary McMullin

Queen's University Belfast

Research output: Contribution to conference › Unpublished paper › peer-review

14 Citations (Scopus)

Abstract

Introduction: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases which contribute to significant morbidity. Symptom management is a prime objective in MPN treatment but current symptom assessment tools have not been validated compared to the general population. Materials and Methods: The MPN-Symptom Assessment Form (MPN-SAF) is a reliable and validated clinical tool used to assess MPN symptom burden. The MPN-SAF was administered to MPN patients (n=106) and, for the first time, General Practice and non-blood relative/family controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between cases and controls adjusted for potential confounding variables. Mean patient scores were then compared to data collected by the Mayo Clinic, USA on 1,446 MPN patients to determine the representativeness of the patient group. Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (p

Original language	English
Publication status	Published - 2016
Event	Haematology Association of Ireland Conference - Athlone, Ireland Duration: 14 Oct 2016 → 15 Oct 2016

Conference

Conference	Haematology Association of Ireland Conference
Country/Territory	Ireland
City	Athlone
Period	14/10/16 → 15/10/16

Cite this

@conference{6b07d49a9d5f42dab8caa956e42926e4,

title = "MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE: RESULTS FROM THE PILOT MOSAICC STUDY",

abstract = " Introduction: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases which contribute to significant morbidity. Symptom management is a prime objective in MPN treatment but current symptom assessment tools have not been validated compared to the general population. Materials and Methods: The MPN-Symptom Assessment Form (MPN-SAF) is a reliable and validated clinical tool used to assess MPN symptom burden. The MPN-SAF was administered to MPN patients (n=106) and, for the first time, General Practice and non-blood relative/family controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between cases and controls adjusted for potential confounding variables. Mean patient scores were then compared to data collected by the Mayo Clinic, USA on 1,446 MPN patients to determine the representativeness of the patient group. Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (p",

author = "Lesley Anderson and Glen James and Duncombe, {Andrew S} and Ruben Mesa and Robyn Scherber and Amylou Dueck and {De Vocht}, Frank and Michael Clarke and Mary McMullin",

year = "2016",

language = "English",

note = "Haematology Association of Ireland Conference ; Conference date: 14-10-2016 Through 15-10-2016",

}

TY - CONF

T1 - MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE

T2 - Haematology Association of Ireland Conference

AU - Anderson, Lesley

AU - James, Glen

AU - Duncombe, Andrew S

AU - Mesa, Ruben

AU - Scherber, Robyn

AU - Dueck, Amylou

AU - De Vocht, Frank

AU - Clarke, Michael

AU - McMullin, Mary

PY - 2016

Y1 - 2016

N2 - Introduction: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases which contribute to significant morbidity. Symptom management is a prime objective in MPN treatment but current symptom assessment tools have not been validated compared to the general population. Materials and Methods: The MPN-Symptom Assessment Form (MPN-SAF) is a reliable and validated clinical tool used to assess MPN symptom burden. The MPN-SAF was administered to MPN patients (n=106) and, for the first time, General Practice and non-blood relative/family controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between cases and controls adjusted for potential confounding variables. Mean patient scores were then compared to data collected by the Mayo Clinic, USA on 1,446 MPN patients to determine the representativeness of the patient group. Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (p

AB - Introduction: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases which contribute to significant morbidity. Symptom management is a prime objective in MPN treatment but current symptom assessment tools have not been validated compared to the general population. Materials and Methods: The MPN-Symptom Assessment Form (MPN-SAF) is a reliable and validated clinical tool used to assess MPN symptom burden. The MPN-SAF was administered to MPN patients (n=106) and, for the first time, General Practice and non-blood relative/family controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between cases and controls adjusted for potential confounding variables. Mean patient scores were then compared to data collected by the Mayo Clinic, USA on 1,446 MPN patients to determine the representativeness of the patient group. Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (p

M3 - Unpublished paper

Y2 - 14 October 2016 through 15 October 2016

ER -

MYELOPROLIFERATIVE NEOPLASM SYMPTOM BURDEN AND QUALITY OF LIFE: RESULTS FROM THE PILOT MOSAICC STUDY

Abstract

Conference

Fingerprint

Cite this